IntegraGen recently published a paper on Oncotarget. The paper delves into a study conducted by EPOC confirming the existence of a relationship between anti-EGFR treatment efficacy and miR-31-3p expression. When levels of miR-31-3p expression are analyzed in those with RAS wild-type metastatic colorectal cancer, patients who can benefit from targeted anti-EGFR therapy can be identified. Consequently, clinicians now have additional insights on tailored therapeutic options for their patients. The study also emphasizes the benefits of precision medicine and the use of miR-31-3p expression testing.
To help with managing metastatic colorectal cancer (mCRC), IntegraGen has launched a simple ready-to-use kit for quantifying miR-31-3p expression in tumor samples. The miRpredX 31-3p kit quantifies miR-31-3p expression in formalin-fixed, paraffin-embedded (FFPE) samples. The company had earlier on announced a licensing agreement with CERBA laboratories to develop a lab-developed test for the quantifying miR-31-3p expression.
Oncotarget is a free-access multidisciplinary journal which publishes papers online on a weekly basis to avail scientific results quickly to a wide audience. The journal was previously dedicated to oncology publications only but has now opened up to other disciplines to spread its impact further. The journal aims to encourage the use of basic and clinical science to fight disease. Not only does it aim to do this, but it also aims to maximize the impact of research through insightful reviews, while eliminating the border between specialties. Additionally, the online journal will now be publishing papers twice instead of once a week to increase the volume, impact, and quality of work disseminated. All papers accepted for publication in the journal will now be directly linked to paginated issues to be published in PubMed. This is with the objective of increasing the frequency of publications of journals on PubMed while in their permanent form.
At the end of 2016, Oncotarget was ranked among the top 50 oncology journals by SCImago Journal & Country Rank. SCImago ratings take into account citations per document, total citations, self-citations, international collaboration, external cites per document, citable documents, among others. As such, this rating is crucial in showing the impact a journal is having on its readers. Given that Oncotarget has now incorporated other fields apart from oncology in the journal, its impact is expected to increase further.